Top Priorities for Cerebroprotective Studies—A Paradigm Shift
Lyden P, Buchan A, Boltze J, Fisher M, Ansari S, Broderick J, Campbell B, Chaisinanunkul N, Chen C, Grotta J, Haddad W, Hareedy R, Hill M, Houser G, Jadhav A, Khatri P, Kimberly W, Koenig J, Korinek W, Landen J, Lansberg M, Latour L, Liebeskind D, Liston T, Lynch J, McGonigle J, Mistry E, Mocco J, Pryor K, Saver J, Savitz S, Sheth K, Solberg Y, Vagal A, Venkatasubramanian C, Ziogas N. Top Priorities for Cerebroprotective Studies—A Paradigm Shift. Stroke 2021, 52: 3063-3071. PMID: 34289707, PMCID: PMC8384700, DOI: 10.1161/strokeaha.121.034947.Peer-Reviewed Original ResearchConceptsComprehensive preclinical assessmentPreclinical assessmentNeurovascular unitMajor public health concernSalvageable brain tissueStroke symptom onsetIschemic stroke treatmentBlood-brain barrierConsensus-based recommendationsPharmacokinetics/pharmacodynamicsClinical trial designPaucity of evidencePublic health concernDifferent brain regionsMechanism of actionCerebroprotective agentTerm neuroprotectionIschemic strokeSymptom onsetStroke treatmentClinical outcomesComorbid conditionsCore injuryClinical trialsStroke model